drugset / Trial / NCT02709187

DP-R208 Pharmacokinetic Study

NCT02709187

Phase 1 Completed 37 enrolled Alvogen Korea
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers

Timeline

Start
2016-03
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan cilexetil Unknown 8 mg
Subject DP-R208 Unknown
Subject Rosuvastatin Small molecule 10 mg

Indications

No indication recorded.